Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The cDNA-derived investigational human parainfluenza virus type 3 vaccine rcp45 is well tolerated, infectious, and immunogenic in infants and young children.

Karron RA, Casey R, Thumar B, Surman S, Murphy BR, Collins PL, Schmidt AC.

Pediatr Infect Dis J. 2011 Oct;30(10):e186-91. doi: 10.1097/INF.0b013e31822ea24f.

2.

Safety and infectivity of two doses of live-attenuated recombinant cold-passaged human parainfluenza type 3 virus vaccine rHPIV3cp45 in HPIV3-seronegative young children.

Englund JA, Karron RA, Cunningham CK, Larussa P, Melvin A, Yogev R, Handelsman E, Siberry GK, Thumar B, Schappell E, Bull CV, Chu HY, Schaap-Nutt A, Buchholz U, Collins PL, Schmidt AC; International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) P1096 Study Group..

Vaccine. 2013 Nov 19;31(48):5706-12. doi: 10.1016/j.vaccine.2013.09.046. Epub 2013 Oct 5.

3.

Evaluation of two chimeric bovine-human parainfluenza virus type 3 vaccines in infants and young children.

Karron RA, Thumar B, Schappell E, Surman S, Murphy BR, Collins PL, Schmidt AC.

Vaccine. 2012 Jun 6;30(26):3975-81. doi: 10.1016/j.vaccine.2011.12.022. Epub 2011 Dec 14.

4.

A randomized, double-blind, placebo-controlled, phase 1/2a study of the safety and immunogenicity of a live, attenuated human parainfluenza virus type 3 vaccine in healthy infants.

Bernstein DI, Falloon J, Yi T.

Vaccine. 2011 Sep 16;29(40):7042-8. doi: 10.1016/j.vaccine.2011.07.031. Epub 2011 Jul 22.

PMID:
21782874
5.

Evaluation of combined live, attenuated respiratory syncytial virus and parainfluenza 3 virus vaccines in infants and young children.

Belshe RB, Newman FK, Anderson EL, Wright PF, Karron RA, Tollefson S, Henderson FW, Meissner HC, Madhi S, Roberton D, Marshall H, Loh R, Sly P, Murphy B, Tatem JM, Randolph V, Hackell J, Gruber W, Tsai TF.

J Infect Dis. 2004 Dec 15;190(12):2096-103. Epub 2004 Nov 8.

PMID:
15551207
6.
8.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in young infants.

Karron RA, Belshe RB, Wright PF, Thumar B, Burns B, Newman F, Cannon JC, Thompson J, Tsai T, Paschalis M, Wu SL, Mitcho Y, Hackell J, Murphy BR, Tatem JM.

Pediatr Infect Dis J. 2003 May;22(5):394-405.

PMID:
12792378
9.

Phase-I study MEDI-534, of a live, attenuated intranasal vaccine against respiratory syncytial virus and parainfluenza-3 virus in seropositive children.

Gomez M, Mufson MA, Dubovsky F, Knightly C, Zeng W, Losonsky G.

Pediatr Infect Dis J. 2009 Jul;28(7):655-8. doi: 10.1097/INF.0b013e318199c3b1.

PMID:
19483659
10.

A replication-incompetent influenza virus bearing the HN glycoprotein of human parainfluenza virus as a bivalent vaccine.

Kobayashi H, Iwatsuki-Horimoto K, Kiso M, Uraki R, Ichiko Y, Takimoto T, Kawaoka Y.

Vaccine. 2013 Dec 16;31(52):6239-46. doi: 10.1016/j.vaccine.2013.10.029. Epub 2013 Oct 19.

PMID:
24144478
11.

A live attenuated bovine parainfluenza virus type 3 vaccine is safe, infectious, immunogenic, and phenotypically stable in infants and children.

Karron RA, Wright PF, Hall SL, Makhene M, Thompson J, Burns BA, Tollefson S, Steinhoff MC, Wilson MH, Harris DO, et al.

J Infect Dis. 1995 May;171(5):1107-14.

PMID:
7751684
12.

A bovine parainfluenza virus type 3 vaccine is safe and immunogenic in early infancy.

Greenberg DP, Walker RE, Lee MS, Reisinger KS, Ward JI, Yogev R, Blatter MM, Yeh SH, Karron RA, Sangli C, Eubank L, Coelingh KL, Cordova JM, August MJ, Mehta HB, Chen W, Mendelman PM.

J Infect Dis. 2005 Apr 1;191(7):1116-22. Epub 2005 Feb 22.

PMID:
15747247
13.

Generation of recombinant human parainfluenza virus type 1 vaccine candidates by importation of temperature-sensitive and attenuating mutations from heterologous paramyxoviruses.

Newman JT, Riggs JM, Surman SR, McAuliffe JM, Mulaikal TA, Collins PL, Murphy BR, Skiadopoulos MH.

J Virol. 2004 Feb;78(4):2017-28.

14.

Phase 2 evaluation of parainfluenza type 3 cold passage mutant 45 live attenuated vaccine in healthy children 6-18 months old.

Belshe RB, Newman FK, Tsai TF, Karron RA, Reisinger K, Roberton D, Marshall H, Schwartz R, King J, Henderson FW, Rodriguez W, Severs JM, Wright PF, Keyserling H, Weinberg GA, Bromberg K, Loh R, Sly P, McIntyre P, Ziegler JB, Hackell J, Deatly A, Georgiu A, Paschalis M, Wu SL, Tatem JM, Murphy B, Anderson E.

J Infect Dis. 2004 Feb 1;189(3):462-70. Epub 2004 Jan 20.

PMID:
14745704
15.

Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers.

Madhi SA, Cutland C, Zhu Y, Hackell JG, Newman F, Blackburn N, Murphy BR, Belshe RB, Karron RA, Deatly AM, Gruber WC, Bernstein DI, Wright PF.

Vaccine. 2006 Mar 20;24(13):2432-9. Epub 2005 Dec 20.

PMID:
16406170
16.

Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children.

Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F; MI-CP149 Investigators..

Pediatr Infect Dis J. 2012 Feb;31(2):109-14. doi: 10.1097/INF.0b013e31823386f1.

PMID:
21926667
17.
18.

A live human parainfluenza type 3 virus vaccine is attenuated and immunogenic in healthy infants and children.

Karron RA, Wright PF, Newman FK, Makhene M, Thompson J, Samorodin R, Wilson MH, Anderson EL, Clements ML, Murphy BR, et al.

J Infect Dis. 1995 Dec;172(6):1445-50.

PMID:
7594701
19.

PIV-3 vaccine National Institutes of Health/Aviron.

Jones T.

Curr Opin Investig Drugs. 2001 Jul;2(7):890-2. Review.

PMID:
11757785
20.

Evaluation of attenuation, immunogenicity and efficacy of a bovine parainfluenza virus type 3 (PIV-3) vaccine and a recombinant chimeric bovine/human PIV-3 vaccine vector in rhesus monkeys.

Pennathur S, Haller AA, MacPhail M, Rizzi T, Kaderi S, Fernandes F, Bicha L, Schickli JH, Tang RS, Chen W, Nguyen N, Mathie S, Mehta H, Coelingh KL.

J Gen Virol. 2003 Dec;84(Pt 12):3253-61.

PMID:
14645907

Supplemental Content

Support Center